SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Panacea Biotec - Quaterly Results

30 May 2025 Evaluate
Net sales declined -15.52%  to  Rs. 679.00 million from Rs. 803.70 millions.The Net Loss for the quarter ended March 2025 is Rs. -123.90 millions as compared to Net Loss of Rs. -13.70 millions of corresponding quarter ended March 2024Operating profit Margin for the quarter ended March 2025 slipped to -124.80% as compared to 71.50% of corresponding quarter ended March 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 679.00 803.70 -15.52 3098.50 3596.00 -13.83 3098.50 3596.00 -13.83
Other Income 60.90 163.90 -62.84 166.20 249.10 -33.28 166.20 249.10 -33.28
PBIDT -124.80 71.50 -274.55 96.90 390.80 -75.20 96.90 390.80 -75.20
Interest 46.40 33.60 38.10 154.60 137.80 12.19 154.60 137.80 12.19
PBDT -171.20 37.90 -551.72 -57.70 253.00 -122.81 -57.70 253.00 -122.81
Depreciation 49.10 51.40 -4.47 202.90 210.90 -3.79 202.90 210.90 -3.79
PBT -220.30 -13.50 1531.85 -260.60 42.10 -719.00 -260.60 42.10 -719.00
TAX -96.40 0.20 -48300.00 -108.30 6.60 -1740.91 -108.30 6.60 -1740.91
Deferred Tax -96.40 0.20 -48300.00 -108.30 0.20 -54250.00 -108.30 0.20 -54250.00
PAT -123.90 -13.70 804.38 -152.30 35.50 -529.01 -152.30 35.50 -529.01
Equity 61.30 61.30 0.00 61.30 61.30 0.00 61.30 61.30 0.00
PBIDTM(%) -18.38 8.90 -306.60 3.13 10.87 -71.22 3.13 10.87 -71.22

Panacea Biotec Share Price

342.05 -15.95 (-4.46%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×